Exelixis Development Agreements

9 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment #1 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial...
Development Agreements
Exelixis
Biotechnology
2017
Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human...
Development Agreements
Exelixis
Biotechnology
2019
Amendment #2 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial...
Development Agreements
Exelixis
Biotechnology
2017
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH
Development Agreements
Exelixis
Biotechnology
DC
2017
COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS 2017 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $25,000 Additional Chair Retainer Fee $30,000...
Development Agreements
Exelixis
Biotechnology
2017
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION DOING BUSINESS AS GLAXOSMITHKLINE AND EXELIXIS, INC. DATED AS OF OCTOBER 28, 2002
Development Agreements
Exelixis
Biotechnology
NY
2013
COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS Exelixis, Inc. 2013 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $20,000 Additional Chair...
Development Agreements
Exelixis
Biotechnology
2013
SECOND AMENDMENT TO THE PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN SMITHKLINE BEECHAM CORPORATION D/B/AGLAXOSMITHKLINE AND EXELIXIS, INC. DATED AS OF OCTOBER 28,...
Development Agreements
Exelixis
Biotechnology
2008
AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT among
Development Agreements
Exelixis
Biotechnology
DE
2005